机构:[a]Department of Hepatobiliary Surgery, The First People's Hospital of Kunming City & Galmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China[b]Department of Hepatobiliary Surgery, Da Ban Qiao Township Public Health Center of Guandu District, Kunming, Yunnan, China
This study is supported by The Joint Special Project Sponsored by Science and Technology Department of Yunnan Province and Kunming Medical University, Postdoctoral Fellow Special Project of The First People's Hospital of Kunming City, The Foundation for Outstanding Young Scientist in Kunming City, The Ten-Hundred-Thousand Project and The Foundation for Clinical Experts Sponsored by Kunming Municipal Health and Planning Commission , Yunnan Province Applied Basic Research (No. 2017FE468(-099)), and Health Technology Project of Yunnan Province (2018NS0162 and 2017NS080).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|4 区医学
小类|4 区胃肠肝病学
最新[2023]版:
大类|3 区医学
小类|4 区胃肠肝病学
第一作者:
第一作者机构:[a]Department of Hepatobiliary Surgery, The First People's Hospital of Kunming City & Galmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
通讯作者:
推荐引用方式(GB/T 7714):
Hu Z,Li L,Ran J,et al.miR-125b acts as anti-fibrotic therapeutic target through regulating Gli3 in vivo and in vitro(Open Access)[J].Annals of Hepatology.2019,18(6):825-832.doi:10.1016/j.aohep.2019.06.016.
APA:
Hu, Z,Li, L,Ran, J,Chu, G,Gao, H...&Chen, J.(2019).miR-125b acts as anti-fibrotic therapeutic target through regulating Gli3 in vivo and in vitro(Open Access).Annals of Hepatology,18,(6)
MLA:
Hu, Z,et al."miR-125b acts as anti-fibrotic therapeutic target through regulating Gli3 in vivo and in vitro(Open Access)".Annals of Hepatology 18..6(2019):825-832